Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.

Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

IVD packaging technology solutions, 9/13

Multisorb Technologies offers its Quality by Design (QbD)-based Calculations through Operations Program. Multisorb’s scientists use the program to determine the optimized sorbent for the application and to manage placement of that sorbent during packaging operations, when required, with the use of a sorbent-specific dispenser. The program and use of a Multisorb system provide an effective solution for ensuring chemical and physical stability for IVD devices through their desired shelf life. For complex stability requirements, optimized sorbent solutions are available with

LC-free MALDI-TOF assay for protein C inhibitor, 9/13

SISCAPA Assay Technologies (SAT) announced publication of a study in Clinical Chemistry demonstrating that one of the company’s MALDI-TOF assays for protein C inhibitor can help identify patients at risk for recurrence of prostate cancer after radiotherapy. The assay measures a proteotypic peptide of protein C inhibitor enriched from tryptic digests of patient serum by anti-peptide antibodies (the SISCAPA, or Stable Isotope Standards and Capture by Anti-Peptide Antibodies, workflow), followed by quantitation using simple MALDI-TOF mass spectrometry. A significant post-treatment

Microbial genotyping system, 9/13

Sagentia has completed initial alpha prototype development of the Resolution microbial genotyping system that it is developing for PathoGenetix. Sagentia has worked with PathoGenetix for the past two years across the full product development life cycle, helping to combine two bread board systems into an intuitive, usable system with a smaller footprint. The Resolution system is based on PathoGenetix’s Genome Sequence Scanning (GSS) technology developed to detect biothreat pathogens in environmental samples. The technology is being developed for faster and

Vitamin D IVD reagent kits, 9/13

AACC 2013 AB Sciex has introduced its Sciex IVD-MS kits, which are a new series of reagent kits for in vitro diagnostic use in conjunction with mass spectrometry instrumentation for clinical analysis in Europe. The first kit is focused on vitamin D analysis and is CE-Marked to meet European regulatory requirements. The Sciex IVD-MS kit for 25-OH vitamin D analysis is designed to help clinicians make diagnoses of vitamin D deficiencies, with the ability to quantitate 25-OH vitamin D2 and

Mass spectrometry systems, 9/13

AACC 2013 AB Sciex has launched in Europe its 3200MD CE-IVDD series, which includes the API 3200MD and 3200MD QTRAP LC/MS/MS systems. The systems are now CE-Marked. AB Sciex, 800-343-1346

Drug screening software, 9/13

AACC 2013 AB Sciex’s MPX TF 1.0 software is designed to accelerate drug screening, with accurate mass-based technology for laboratories performing clinical research. The software delivers faster turnaround times, increased sample throughput, and lower costs compared with single-stream, mass spectrometry (MS) methods. With the MPX TF software, researchers can increase throughput by as much as twofold. This is made possible by enabling the use of two parallel liquid chromatography streams. The ability to stagger chromatographic runs while collecting sample data

ELISA procedure to quantify human IgG, 9/13

The Binding Site now offers a specifically formulated and optimized ELISA procedure for the quantitation of intact human IgG from matrices containing non-human proteins. The assay is for clinical, biopharmaceutical, and medical researchers. The ELISA uses sheep polyclonal antibody, specific to the Fc and light chain regions of human IgG for capture and detection respectively, ensuring that only intact human IgG is quantified. The assay virtually eliminates any cross-reactivity to common laboratory species (for example, mouse, rat, primate) and to

TMB substrate-chromogen, 9/13

The Binding Site now offers a substrate-chromogen containing 3,3’,5,5’-tetramethylbenzidine (TMB). Designed for use as an integral component in peroxidase-based, colorimetric techniques, the TMB chromagen-substrate is for use in enzyme immunoassay test procedures. The TMB substrate-chromagen demonstrates decreased sensitivity to light when compared with other peroxidase chromogens and can be developed without any special precautions. Offered in a liquid-stable, ready-to-use format, the product displays exceptional shelf-life stability, lot-to-lot consistency, and specific performance characteristics. The TMB substrate-chromagen also permits for a safe

Human protein antibodies, 9/13

The Binding Site now offers a specialized line of anti-human serum protein antibodies. Through the use of a patented technique, which yields highly specific antibodies, all available products display a high degree of purity, shelf-life stability, and lot-to-lot consistency. The range of specialized antibodies includes those involved in blood coagulation, complement activation, acute-phase reactants, immunoglobulin response, and others. The antibodies can be conjugated to biotin, fluorescein, horseradish peroxidase, rhodamine, and others. The Binding Site, 800-633-4484

Water purification system, 9/13

Thermo Fisher Scientific has launched its Barnstead GenPure xCAD Plus water purification system, which has technology that allows simultaneous dispensing from three remote dispensers for exceptional flexibility and ease of use in shared laboratory environments. In addition to its advanced dispensing technology, the Barnstead GenPure xCAD Plus is easy to use and comes with leak detection, feed water monitoring, and all the consumables necessary to get started, allowing for simple ordering and setup. The system, now available in North America

MARKETPLACE

TRENDING